ReNeuron Group plc
RENE.L · LSE
9/30/2023 | 3/31/2023 | 9/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £157 | £92 | £438 | £345 |
| % Growth | 70.7% | -79% | 27% | – |
| Cost of Goods Sold | £2,177 | £1,477 | £132 | £148 |
| Gross Profit | -£2,020 | -£1,385 | £306 | £197 |
| % Margin | -1,286.6% | -1,505.4% | 69.9% | 57.1% |
| R&D Expenses | £2,177 | £1,477 | £2,986 | £3,728 |
| G&A Expenses | £1,280 | £1,456 | £863 | £888 |
| SG&A Expenses | £1,280 | £1,456 | £1,594 | £1,627 |
| Sales & Mktg Exp. | £0 | £0 | £731 | £740 |
| Other Operating Expenses | -£2,177 | -£1,477 | £0 | £0 |
| Operating Expenses | £1,280 | £1,456 | £4,580 | £5,355 |
| Operating Income | -£3,300 | -£2,841 | -£4,274 | -£5,158 |
| % Margin | -2,101.9% | -3,088% | -975.8% | -1,495.1% |
| Other Income/Exp. Net | £72 | £2 | £2,365 | £2,611 |
| Pre-Tax Income | -£3,228 | -£2,839 | -£3,818 | -£5,094 |
| Tax Expense | -£387 | -£607 | -£642 | -£639 |
| Net Income | -£2,841 | -£2,232 | -£3,176 | -£4,455 |
| % Margin | -1,809.6% | -2,426.1% | -725.1% | -1,291.3% |
| EPS | -0.05 | -0.039 | -0.056 | -0.078 |
| % Growth | -27.4% | 29.9% | 28.8% | – |
| EPS Diluted | -0.05 | -0.039 | -0.056 | -0.078 |
| Weighted Avg Shares Out | 57,174 | 57,161 | 57,090 | 57,056 |
| Weighted Avg Shares Out Dil | 57,174 | 57,162 | 57,090 | 57,056 |
| Supplemental Information | – | – | – | – |
| Interest Income | £182 | £106 | £37 | £17 |
| Interest Expense | £16 | £0 | £10 | £7 |
| Depreciation & Amortization | £80 | £87 | £132 | £148 |
| EBITDA | -£3,220 | -£2,754 | -£2,005 | -£2,431 |
| % Margin | -2,051% | -2,993.5% | -457.8% | -704.6% |